tClinical Trials

A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients with Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations
Jeff Rothstein, MD, PhD – Principal Investigator

Brain metabolism in amyotrophic lateral sclerosis (ALS): A 3 Tesla magnetic resonance spectroscopy study
Mona Mohamed, MD – Principal Investigator

Safety and Tolerability of the Ketogenic Diet in ALS
Vinay Chaudhry, MD – Principal Investigator

A Single and Repeat Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of GSK1223249 in Patients with ALS.
Andrea Corse, MD – Principal Investigator

Generation and Characterization of Cell Lines for ALS
Nicholas Maragakis, MD – Principal Investigator
(Currently only enrolling patients with confirmed familial ALS)
Contact: Betsy Mosmiller (p) 410-502-0495 | emosmil1@jhmi.edu

Skin biopsies to generate cell lines for study of ALS
Nicholas Maragakis, MD – Principal Investigator

A Multicenter Study for the Validation of ALS Biomarkers
Nicholas Maragakis, MD – Principal Investigator

Currently enrolling NEALS Clinical Trial (Packard Affiliate)
Clinical Trial of Ceftriaxone in Subjects With ALS
Merit Cudkowicz, MD, MSc. – Principal Investigator
Contact: Sarah Titus, MPH, (p) 617-726-1398 | stitus@partners.org